- Report
- February 2024
- 30 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Report
- February 2024
- 30 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Report
- February 2024
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- February 2024
- 30 Pages
United States
€2147EUR$2,250USD£1,799GBP
- Report
- February 2024
- 30 Pages
United States
€2147EUR$2,250USD£1,799GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- February 2024
- 204 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4724EUR$4,950USD£3,958GBP
- Report
- February 2024
- 360 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- April 2023
- 112 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- October 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- June 2021
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- March 2020
- 90 Pages
Africa, Middle East
From €1432EUR$1,500USD£1,199GBP
- Report
- August 2022
Global
From €945EUR$990USD£792GBP
- Report
- January 2024
- 147 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- August 2024
- 84 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- May 2023
- 105 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- June 2022
- 176 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2022
- 41 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2022
- 37 Pages
Global
From €1909EUR$2,000USD£1,599GBP

Uveitis is an inflammatory condition of the eye that can cause vision loss and other complications. Immune disorders drugs are used to treat uveitis and other immune-mediated diseases. These drugs are designed to reduce inflammation and suppress the immune system. Commonly used drugs include corticosteroids, immunosuppressants, and biologics. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the activity of the immune system. Biologics are used to target specific parts of the immune system and reduce inflammation.
The uveitis drug market is a rapidly growing segment of the immune disorders drugs market. It is driven by the increasing prevalence of uveitis and other immune-mediated diseases, as well as the development of new drugs and treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more